Tosoh Bioscience

Traditionally, producing biotherapeutics such as monoclonal antibodies required a multi-step process to remove impurities, including host-cell proteins, DNA, adventitious viruses, and antibody aggregates. However, by converting the process from batch chromatography to multi-column chromatography (MCC), there is potential to reduce costs and shorten production times for the capture and purification of high-quality mAbs.

Transitioning to intensified, continuous chromatography can increase efficiencies and decrease time and cost when analyzing protein A.

A two-step mAb purification process was developed, tested, and intensified. Increased process productivity, while exhibiting robust impurity clearance and high yield, was achieved.

Webinar Date/Time: Tuesday, December 12, 2023 Session 1: 9:00 am EDT | 1:00pm GMT | 2:00pm CET Session 2: 1:00 pm EDT| 12:00pm CDT| 10:00am PDT

Intensified continuous chromatography, a type of Multi-Column Chromatography (MCC), has emerged as a valuable technique in downstream bioprocessing that enables increases in productivity. In this podcast, MCC Product Specialist, Jennifer Knister, will discuss how adopting MCC can reduce costs, decrease suite time, and lead to higher resin utilization, along with why these benefits are particularly worthwhile in multi-product facilities.

Intensified continuous chromatography, a type of Multi-Column Chromatography (MCC), has emerged as a valuable technique in downstream bioprocessing that enables increases in productivity. In this podcast, MCC Product Specialist, Jennifer Knister, will discuss how adopting MCC can reduce costs, decrease suite time, and lead to higher resin utilization, along with why these benefits are particularly worthwhile in multi-product facilities.

A two-step mAb purification process was developed, tested, and intensified. Increased process productivity, while exhibiting robust impurity clearance and high yield, was achieved.

Webinar Date/Time: Tuesday, September 12, 2023

While continuous bioprocessing has been around for decades, it is becoming more attractive as technological advances and new trends in the biopharma industry emerge.

Transferring from a conventional batch mode to a multi-column chromatography (MCC) process significantly increases the productivity of the Fab fragment capture.